About Sagimet Biosciences
Sagimet Biosciences (NASDAQ:SGMT) is a biopharmaceutical company dedicated to developing a range of novel therapeutics aimed at addressing critical needs in metabolic diseases, with a significant focus on nonalcoholic steatohepatitis (NASH) and other liver-related disorders. Their innovative approach leverages unique insights into metabolism and disease mechanisms to design targeted, effective treatments. Currently, Sagimet Biosciences is advancing its lead candidate through clinical trials, demonstrating a commitment to improving patient outcomes in areas with significant unmet medical needs. The company's objectives are deeply rooted in advancing healthcare through groundbreaking research, aiming to deliver transformative therapies to patients worldwide.
Snapshot
Operations
Produtos e/ou serviços de Sagimet Biosciences
- FASN Inhibitor Program focused on developing treatments for metabolic diseases, NASH (non-alcoholic steatohepatitis), and cancers.
- Clinical trials for non-alcoholic steatohepatitis (NASH) treatment with novel FASN inhibitors.
- Development of novel therapeutics targeting fatty acid synthase (FASN) to address various cancers.
- Research on metabolic diseases treatments leveraging their proprietary technology platform.
- Partnerships for advancing research and development in therapies for liver diseases and metabolic disorders.
- Pipeline expansion into new therapeutic areas by exploring the role of FASN in different diseases.
equipe executiva do Sagimet Biosciences
- Mr. David A. HappelCEO, President & Director
- Mr. Thierry ChaucheCFO & Principal Accounting Officer
- Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.Chief Medical Officer
- Mr. Urs Greber Ph.D.Co-Founder
- Dr. Lucas Pelkmans Ph.D.Co-Founder
- Dr. Marie O'Farrell Ph.D.Chief Scientific Officer
- Ms. Elizabeth Rozek Esq., J.D.Chief Legal & Administrative Officer
- Mr. Robert D'UrsoSenior Vice President of New Products